# T I III III

Transboundary and Emercing Diseases WILEY

# COVID-19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates

# J. Wes Ulm 🕑 | Stanley F. Nelson

Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, CA, USA

#### Correspondence

Jacob Wes Ulm, Department of Medical Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Email: wes\_ulm@post.harvard.edu

# Abstract

Repurposing of existing anti-viral drugs, immunological modulators and supportive therapies represents a promising path towards rapidly developing new control strategies to mitigate the devastating public health consequences of the COVID-19 pandemic. A comprehensive text-mining and manual curation approach was used to comb and summarize the most pertinent information from existing clinical trials and previous efforts to develop therapies against related betacoronaviruses, particularly SARS and MERS. In contrast to drugs in current trials, which have been derived overwhelmingly from studies on taxonomically unrelated RNA viruses, a number of untested small molecule anti-virals had previously demonstrated remarkable in vitro specificity for SARS-CoV or MERS-CoV, with high selectivity indices, EC<sub>50</sub> and/or IC<sub>50</sub>. Due to the rapid containment of the prior epidemics, however, these were generally not followed up with in vivo animal studies or clinical investigations and thus largely overlooked as treatment prospects in the current COVID-19 trials. This brief review summarizes and tabulates core information on recent or ongoing drug repurposing-focused clinical trials, while detailing the most promising untested candidates with prior documented success against the aetiologic agents of SARS and/or MERS.

#### KEYWORDS

anti-viral agents, COVID-19, data mining, drug repositioning, pandemics, SARS

The unprecedented public health, economic and social challenges engendered by the current COVID-19 pandemic necessitate an urgent search for effective clinical interventions to help reduce viral load and epidemiological spread, improve prevention and control, and stem the tide of rising morbidity and mortality (Spinelli & Pellino, 2020). Due to the time lag of vaccine trials and de novo drug development based on standard drug-target modelling, compound screens and multi-phase clinic testing, the most rapid and practical approach towards new clinical options lies in drug repositioning of proven or promising infectious control modalities (Li & De Clercq, 2020). For SARS-CoV-2, the aetiologic agent of COVID-19, this effort may be significantly assisted by previous endeavours to develop therapeutics for two prior smaller epidemics, both caused by closely related coronavirus types. Severe acute respiratory syndrome (SARS) and Middle Eastern respiratory syndrome (MERS) each originated from outbreaks of betacoronaviruses with significant sequence and structural similarity to the SARS-CoV-2 betacoronavirus (Zhu et al., 2020).

Thousands of COVID-19-related clinical trials have been proposed or launched since January 2020, at multiple global sites, with many seeking to assay for efficacy of various repurposed drugs against SARS-CoV-2—most available on the National Library of Medicine's registry of clinical studies, others scraped from text-mining of the available literature. Figure 1 summarizes an early snapshot of such clinical investigations, focusing on 53 repurposing-based trials noted to be in planning or progress as of 17 April 2020, on the basis of the tested drugs, targets or mechanisms, preliminary efficacy studies, current and prior literature on the drug's efficacy for betacoronavirus-related disease and the specific designating information for the relevant trials themselves including their ansboundary and Emerging Diseases

		Profilm neualist for	DOI of performed	OOI of profee christel									
Onug	Target ar moshanism (if knewn)	Mill CrV-3 Industry and reports (#	prior studies 5203, MERL or related	In fails, same requests, or in when shadlen SARS Carl.	similarity identifies and phase (Feynlade)	Bisely L size, sincetory, est. completion data	Shully 2 size, skrackure, exi- completion date	liwly 3 size, simetare, ex- completion data	Goody & size, structure, est, completion clube	Bady Exile, structure, est. completion date	Sholp E size, structure, ext. sompletion date	Sharly 7 size, structure, est. completion date	Stady & size, skrackure, exi. completion date
		applicable	18.3005/3pharenthe	Group 13		\$CT6075ND-60	MC784313228-158						
Selarare	Risk-dependent Brisk polymerase		10.1177/304830661 6754463.		NCTINETSNEL NCTOADDEEDS	participants, randomized open-label sequential	perticipents, randomiced open-label penaliel						
			66.0%/36.21Kh/9ja 0-30.627			April 30, 2830	May 2029						
		dista in ACM			INVO SOLIDARITY, IPDERM Discovery	sino soucientiti laga-	INCOMESSION DECOMPS (INCOMESSION) 3300		CORD 29 Theorem	ACTIVITIES 400			
nenderare	RNA-dependent RNA polymerizer	(Addue et al.) and is not call an	4.443953, 10.3030543465	, 13.3080/41422-029- 0282-0	NC104382708 (reparked access),	sade, multi-center, sandembed apen-fabel, officerator 708	participants, randomiced open-tabel parabel accessed configuration	NCOULTINE TIA	randomand-daubit-blin parathel antigroment,	open-balet parallet antigrowent, cingte center			
		(Wang et al.)	CED-13368-6		NCTOLERING (share 1) NCTOLERING (share 1)		Manh 2003		multi-center - April 1, 2023	- May 2023			
		effective at reducing siral load in sites (here											
10.54 lot supplies	Ahla dependent Bhia polymerate	sell subury) and solucing clinical	18.1177/999682800 406588300, 10.13010028.65.19	10.1301/0028.85.15.997 890-1.64	(that in planning)								
		septelse in sise Emical (Sheahan en al 1	357559x3.54										
		1.114	129-13943-4		AVIO SOLEARTY,								
		mised efficaça in	2 2 2 2 10 10 10 10 10 10 10 10 10 10 10 10 10	10.3856/MCMcv2R1212	OCTIVALISMO, ACTIVALISMO,	WHO SOLOANTY large	INSERIM Discovers (INCT043155452:3300	ACTIVASISTS SSI anticipants conferminal	NC1040E1530: 250	MC104290729-13 perticipants, non-	ACTIVASENTE LIN	perticipants, perticipants,	participants.
lightenich/tenevit	viral protects inhibitor	2 small Chinese 9 lob (Can et al.,	05-085, (PM-0: 1.4600006;	18. 1016 L pri 2800 00 H	MC164387655 [phose 2] MC164291729 [phose 4]	sole, malticenter, randemised spon-label, otherwise 204	perticipents, randomiced open-label penaliel	open-label penaliel assignment, single centar	coen-label parallel ecolormont, molti-cento	nandomized open-label single prosp assignment,	spen-label parallel sesignment, multi-center -	labd parallel assignment, multi-	label parallel serigement, single
		Conformi	18.1136/thotax.300 3.313658,		SCTHOLENT, SCTHOLESSE	0.01010.01	March 2022	February 20, 2021	- May 2830	2820	June 36, 2028	centar - April 54, 2021	131607 - January 22, 2015
			100		PR. INCLUSION	NC1042012107-240							
83008/vitamentr	stral protects introduce				NETOIZNINO	participants, candomized oper-tabel parallel							
						kone RO 2020 ACTIVATION NO							
siameranti bakistaati	situal protocase initialitor				ACTINUUS (shee 3)	participants, sandamiand spara label parallel							
						December N, 200 December N, 200	KTM INNE VI	LTD/10984-188					
umileranie (arbeida)	membrane facion				ACTIVATIONS, ACTIVATIONS,	participants, sandemized open-label separatial	participants, randomized open-label panaliel	participants, sandomized open-label parallel					
					ACTIVATION (phase 4)	ecolgement, single senter - April 30, 2830	solgoment, single centur - February 35, 2821	sosignment, single centur - Becember 36, 3009					
boartan	anglalansin Trisophir Lyae		20.1038/wr4287		AC706112009 Junior 20	participants, candianized stantite-blind aacidet							
	1905					anagronaeri, anulii cardar - Agril 1, 2011							
		effective in cell calture (Along et al 1 Journ		1010004402402	NO SO DARTY	www.souowent.targa-	NCTORORIZON: 40,000	NCTHORSELSER					
diorequire	vital uncosting (endosome additication), ACE2 recepto	the spectic indo that		8282-8, 2018933/06/000217	NCTINUOUSER, NCTON2BNSOR	stale, multi-center, tandambod apon-tabol, officerular 708	double-blind parallel assignment, multi-cantor	open-tabel potaled assignment, single centar -					
		rydrosythoroga ne (fao-id al.)				OT THE R. P.	April 2021	Ndriany 38, 2821					
		callure, test too than chierapure			Iphise 2.31 NCT04308080	ACTOEXDAMA 3000	ACTIONOVED 114	ACTIVAL1333-30	HEDRA MAI PRETORIZARINE 100				
hydrosychionopies	visd seasating (milesone assolitaation), 6232 recepto	(Yan et al.) improved time to		10.1301(0020.01.22.200 ME718	jphese 21. ACTORNIST	quality/initial parallel autoperant, single senter	uper-lakel panallel autgement, realti santar	oper-lakel panalel anagement, single center	participants, ramilianter quantuple initial paralle				
		(1700) (Oven et el.)			Hel (NCTOES18885, phase 3)	May 12, 3029	May 3028	February 25, 2830	center) - Marsh 22, 302				
hermiter the	Berter				MCR4 VIIIA	6CT84(TSNE-60 participants, randomized costs, label							
#-, (Kite III)						Approximate sequential excilationent, single contor - Appl 30, 2030							
interferon beta (33)	collubr and viral induction		18.3000/9856/9-09 1		ipert of cambination through that is		or other	with the second s			_		
interferan oldta (***	onlubr and work induction	-		-	NCTIMITIONS, INCOMENSING ADJACENT	<ul> <li>POTIVAL 60 participants, candonized open-table orgunation</li> </ul>	porticipants, randomized open-table costshift	eccentroliters is a control oper-table control oper-table control	-	-	-		
					NCTORES JUST	April 80, 2830	augeneest, math-cantor Jane 30, 2020	anteriment, under center - Lanuary 22, 2011					
interferor status ?~				-		ACTINITIZE 11 participants, more randomized score labor	_	_	-	-			
pegdated (Pegarget)	wilder and industries				ne.104211728 (share il)	single group antigrammed, single context - Itlands 18,							
<u> </u>						2008 6CT34291229-11 8xTiclocott							
renderer becombinen Phalpho-likej	collular antiviral induction		10.1386/1475-1887 14-6	1	NCT04251725 Johnse 4	randomical open-label single group assignment							
						single conter - Munch 13, 2009							
brocureb	VEEF Granular				NCTOR/THE M	9C194275454-29 participants, non- randomicad cosm-ipAul							
	pomeability				(phase 2.3)	single group assignment, single center - May 2020							
canadat.	THEFE CONTRACTORS	vitedare is out subure reducing viral entry	12, 13, 14,1128/W/2009	12.3216( orf.2228.02.35 2	pratio planning)	_	_	_	-	-			
officiencia.	description and	(hollmann et al.)	33		just of cardination								
Transfer	hydroryddianopine				through triab.	4CT2423423423-294							
	anti-fileratic (procollagers i					open-label panallel sexignment, single senter							
pitenidore	and it, granth factors)				MC104282902 (phase 3)	ture 1, 2030 9CT34006302-60							
						open-label penalid sesignment, single contor							
strandino	anti-Maratic				NC164308317 (phase 4)	May 1, 2021 9CFIHIT1528, 300	9C71H273581 40						
	anti-fibratic, cytokiwi donn demosromeđu bitov, arti-				MCTOREPORT Means 11	deuble-blind parafiel deuble-blind parafiel despensest, mato-center	guadrupio-blind parallel guadrupio-blind parallel guadrupio-blind parallel						
Bubdoende	(protonoutory)				NETOALTERN (Plane 1)	hano 30, 2003	May 80, 2820						
	Target or mothanium (#	SMIS-CeV-2	GOL of portinent prior studies SAIS,	DOI of prelim-divisal trials, case reports, or in	dinkaltrials.grv (B()) a	Study 3 site, structure, ext.	Shady 2 size, structure, est.	Study 3 site, structure, ext.	Study & size, structure,	Starty 5 size, structure,	Shuda K size, skrathure,	Shely 7 size,	Starty 5 star.
(Fing	known)	reports (F reports (F	NERS, or related RNA vinceto	vitre studies SARS-GrV- 2/109/8-15	and phase \$7 evaluaties	completion data	completion date	completion data	est completion-dute	est, completion data	est, completion date	completion date	completion data
						ACTIVATION 124							
						participants, randomized							
Carolina da	excolide antibiotic (ennuromodulation, anti- adianeurace)				WCT64206503	participants, randomized open-label perailed sealphrown, single context – ladecore 18, 1911							
cannyca	nacolide antiliotic Jennanomodulation, anti- edianesezanji				NCT64208503 Sphose 45	participants, tandomised open-tabli possibili belgeneute, single canter – february 28, 2031 WCTM10208, 408 participants, tandomised							
cantriquis	macolide antikiotic (immarcenodulatice, anti- edianestrany) 8:4 receptor (immarcenodulatice, anti-				WCT14208503 (phose 4)	pericipants, randomised open-label possifiel belightness, angle contex- federatory 28, 2021 SCT04115288, 400 pericipants, randomised quadruph-blind parallel belightness, rangle centex-							
cannopoli sardunua	macolide antibiotic (ennueroexclution, anc- edianescary) 8.4 receptor (ennueroexclution, anc- edianescary)	el'hollou in reducing			NCTG4200503 (phone II) NCTG6223278 (phone II)	perfictures, surdomized open-bod openial subgrower, ingle canter – Advisor 28, 2023 Sertisparts, surdomized quadrage-blind parable subgrower, single center – March 28, 2023 SCTBEISDOR, IM							
cannycis sa flanab	macolide antibiotic (immanomobilition, anti- adiametary) 8.4 margine (immanomobilition, anti- ediametary) 8.4 merupter (immanomobilition, anti-	effeslive in reducing produkting in some Drivene kriel (kr			NCT(#200503 (phose 4) NCTORECUTINE (phose 2)	persidgents, rendemined opp-to-bid possibil outgomente, robust control- federatory 28, 2023 VETPELISINE AND persongents, rendemined packing-robust, opp-control- dia-bid 2023 March 24, 20							
cattingcia cariterado incilizamedo	supplied problems (innumerical problems), and deformation (innumerical problems) (innumerical problems) (innumerical problems) (innumerical problems) (innumerical problems) (innumerical problems) (innumerical problems)	effective to roboting evolution or are obtained to be at al.)		4.330%205300.8004	NCTEADOSCO (shown 4) NCTEATORITIE (shown 2) NCTEATORITIE	Dersicipanta, randomizard opp-hadropostali augenetic, jogie costar- habrizery JB, 2023 40/2047 JB, 2024 40/2047 JB, 2024 40/2047 JB, 2024 40/2047 JB, 2024 40/2047 JB, 2024 40/2047 JB, 2024 40/2							
carlingcis La florada	supported problems: internancempolations, anti- adianearanyi between anti- adianearanyi between anti- between anti- bet	effective in reducing producing control by in serve Ordeneze trial (ke et al.)		18 33094/380005 88026	NCTO4208000 (share 4) NCTO4208218 (share 2) NCTO4208218	participants, understadd analgenest, ingle castar- february 38, 2011 9279-9281, 2011 9279-9281, 2011 9279-9281, 2013 9279-9281, 2014 9279-9281, 2014 9279-9291, 2014 9279-9279, 2014 9279-9279, 2014 9279-9279, 2014 9279-9279, 2014 9279-9279, 2014 9279-9279, 2014 9279, 2014 9279							
antinycis antianab antiourab Englinest	Inscribe arabitotic primaromotivation, am- adiametary in a diametary in a diameta	effective to reducing resolution (some or total (some et al.)		13 33014/20005.80004	NCT04200500 (shore 4) NCT042012138 (shore 2) NCT042012138	perfolgens, sectorologi and periodial control and periodial control feature and a control feature and a control performance and a control and opportunity of periodial departure and a control departure and a control department, and a control department, and a control department,							
antinpcis antionala antionala antionala antionala Salmo	nacolia anbieto: enanceneou dellaco, an- elfanestrary i E. E. magliot Bernancia Allon, ani- denessi della anti- ante anti- provance anti- la della pole - 3 desphete tomar consoliation, ani- della magliotta - 3 desphete tomar consoliation, ani-	effective in reaching matching is used Datase trid (for et al.)		18 33014/200005 80026	90754200500 (phone ii) 9075620339 (phone 2) 9075620339 (phone 2) 9075620339 (phone 2) 9075620339 (phone 2)	perfolgenze, servebrook uingenneer, ongle zottet diskenary 28, 2011 SCT4121284, 2011 SCT4121284, 2011 SCT4121284, 2011 SCT41212284, 2011 SCT41212284, 2011 SCT41212284, and participant, servebrook and upper load grandel perfolgenze, servebrook sct41284, 2011 SCT41212284, 2011 SCT41212284, 2011 SCT41212824, 2011 SCT41212824, 2011 SCT41212824, 2011 SCT41212824, 2011	507944653.10						
annych ar tarab solicerab deplinest aculeznác balró	Inscribe antibiotic permanentechnickos, ami- adiametaraya bi fi megalion permanenalization, ami- demensionali permanenalization, ami- demensionali permanenalization, ami- demensionali permanenalization, ami- demensionali permanenalization, ami- demensionali permanenalization, ami- demensionali permanenalization, ami- adiametaraya permanentechnickos, ami- adiametaraya	ef Mediane in reducing reducing to some object of planet of eff		13 33094/162005 88026	90754200500 (phone ii) 10706203338 (phone 2) 1070620538 (phone 2) 1070620538 (phone 2) 1070620538 (phone 2)	anticipant, singhoman, singhoman, jingho tantar, singho tangho tantar, singho tangho tangho tantar, singho tangho tangho tangho tantar, singho tantar, singho tantar, singho tangho tang	\$07\$434531.07 #27504651.07 #2750466.06.0000000000000000000000000000000						
antopoli antonah antonah antonah antopolinah antopolinah	moodia antibiotic antiananomodiaticos am- adiananomodiaticos am- adiananomodiaticos am- balananomodiaticos am- adiananomodiaticos am- diananomodiaticos am- diananomodiaticos am- diananomodiaticos am-	el Postor in reducing enveloting to enveloting to enveloting to at al 1		13 33094(160000 ABROR	NCTR4200500 (Inter II) NCTR4200501 (Inter II) NCTR420508 (Inter II) NCTR420508 (Inter II) NCTR420508 (Inter II) NCTR420508 (Inter II)	and sparse, surphomough and provide a constraint and provide a constraint Constraint and a constraint Constraint and a constraint and provide a particle and pro	5/794/4/031.07 par/signary, acclorate par/signary, horizonae Alagonae, horizonae						
annyca er terete softwerte eutoponet eutoponet eutoponet	enable enabled in a settleter enablemen enabled on an enable enable enable enabled on an enablement	el'hilor in reduite andal y was Doine trid fis a di		53 13074/98000 ABOVE	NJ TRADUDO) JACOGRADI Alexe 2 NTOCRADI Alexe 2 NTOCRADI Alexe 2 NTOCRADI Alexe 2 NTOCRADI Alexe 2 NTOCRADI Alexe 2	androgenes, surgeborosoli asinghenes, engle serar- land hard and the serar- estimation of the serar- participant, surgeborosoli and serare serare serare serare participant, surgeborosoli and serare serare serare serare band y and the participant, surgeborosoli and serare serare serare serare band y and the participant, surgeborosoli and the serare serare serare serare band y and the participant, surgeborosoli and the serare s	SUTPLANDED BY SPITSPARS, according to Spitspars, accor						
armus artanak antionnak antiophina antiophinaton CEEN	Isociale antibiotic infarmacino difficulto, amb infarmacino difficulto, amb infarmacino di ficiale e il seguito il e i seguito	Ministra in reducing and and a Dome trial for a still		14 1074/20004 88094	NETERISTICA Johne P, NETERISTICA Jones 21 NETERISTICA Jones 21 NETERISTICA NETERISTICA NETERISTICA NETERISTICA NETERISTICA	nerginer, andersam geschlag candid Charles and an andersam geschlag candid Charles and an andersam geschlag candid and an andersam geschlag and an andersam geschlag an andersam geschlag and an an an an an an an an an an an a	5075044031.00 processor and an and a second processor and a second procesor and a second processor and a second pr						
(2019)(3 external boltoned) copioned copioned external-particular external-particular external-particular external-particular external-	modele melocitic desensary	Produce in- reaching evolution of the pro- order of the pro- ent of the pro- ent of the pro- ent of the pro- ent of the pro- tect of the pro-		13 1374/2009 BEEK	NETRADUCTO Datase 40 NETRADUCTORE barres 21 NETRADUCTORE barres 21 NETRADUCTOR NETRADUCTOR NETRADUCTOR NETRADUCTOR	program, submitted production and production communications and production communications and production productions and production production and production submitted productions and pro- teories and production and pro- teories and pro- team and pro- page a	S21514503.07 pretrates, subdata						
entransis enternational tespionest endernational entrapportestore entrappo	modelanderskoller inderenderskel denerster denerster 1. et rengele innernerskel innernerner innernernerner innernernernernernernernernernernernerner	effendeurin rechning erefnidity is orea of all all		13 3379/2009 BICS	NCTORONOOO (phone 4) NCTORONOU (phone 2) NCTORONOU (phone 2) NCTORONOU (phone 2) NCTORONOU (phone 2) NCTORONOU (phone 2) NCTORONOOO (phone 2)	and general constrained general constrained and general History TEX 2013 History TEX 201	SCHUMSLIN AND SEA AND AND AND AND AND AND AND AND AND AND AND AND AND AND AND AND AND						
antoret auforeta balloaret auforeta auforeta autopasaione autopasaione	Nordersteiner Nordersteiner Anterpreckense	Plantas (r) entening outer and plantas outer and plantas et al.			NETORIALIST (Anno 2) NETORIALIST (ANNO 2)	androgeness consensus androgeness consensus to the second and consensus to the second and consensus and consensus and consensus and consens	SPIRUHUL IN Private Automatica Statistics of the Automatica Statistics of						
annan edinad baland autoritization autophysionic autophysionic autophysionic autophysionic autophysionic	Incode predictions incode and an experimental incode an experimental incode an experimental incode an experime	Plantas tr enkning Oshana trad pla et al.			VCTRA20000 phone 6 VCTRA20001 branc 2 VCTRA20001 branc 2 VCTRA2001 branc 2 V	nergener, sowienleid officielle of the source source of the sourc	V/HUMSI II WHUMSI II HIPPORT, MOTOR HIPPORT, MOTOR HIPPORT						
entransk entransk entransk entransk entransk entransk entransk entransk entransk entransk	Incode methods and a second se	Productor enducing concluding to enducing the set of the set of th			VCTRADBOD phone 6 VCTRADBOT VC	andrageness consensus andrageness consensus consensenses consensus consensus consensus consensus consen	K/140401.0F program, solvening and an out-of-solvening basedon (A. 520)						
program	monthermolecular monthermolecular sectors and an annual sectors and an annual sectors and an annual sectors and an annual sectors and an annual sectors and an annual sectors and annual sectors and an annual sectors and an annual sectors and an annual sectors and an annual sectors and annual sectors and an annual and annual sectors and an annual annual sectors and annual sectors and annual annual sectors and annual sectors and annual sectors annual sectors annual sectors annual annual sectors annual sectors annual sectors annual sectors annual sectors annual sectors annual sectors annual sectors annual sectors annual sectors annual sectors annual sectors annual sectors annual sectors annual sectors annual sectors annual sectors	Madara nakang ang ang ang ang ang ang ang ang ang ang			NCTRADBOD phone 6 NTRADBOD NTRADBIT NTRADBIT NCTRA	nerviews another and a second	Critocola di Antagenta Antagenta Secolaria Sec						
program	montenentiek instrumenten en antenentiek en antenen	effedra y notestig beneris va for et el			VCTRADBOD prime 0 STRADBOT STRADB	percent services and services a	SUSIANS IN pro-Mayor Annual pro-Mayor Annual Encoder IN 2007 Professional IN Professional IN P						
generals or faceto automatic automat	monitorenergia. energia energia energ	Holory			VETEX20000     phote 0     STEREINTER binnes 0     STEREINTER binnes 0     stressesses     stressesses     vetex20     ve	processors and sectors and sec	CTEMPET B Process Annual Process Annual Beneficial (Contempeted on the Contempeted Beneficial (Contempeted on the Contempeted Process Annual Process Ann	K70000 9					
program	nacharana anacharana a hanarana a hanaranana a hanarana a hanaranarana a hanarana a hanarana a hanarana a hana				нстразвод от также протоколого от также п	production submitted submitted by the submitted submitted by the submitted by the submitted by the submitted submitted by the submitted by the submitted by the submitted submitted by the submitted by the submitted by the submitted submitted by the submitted by the submitted by the submitted submitted by the submitted by the submitted by the submitted submitted by the submitted by the submitte	Virtection as Virtual	47760819.99 3039245, 200604					
generate an directed Sectore and California di Anti-Approximations California	modelensity extension	Panhar to making making meaning making the second second second second of (			NCTERADEOUS           NCTERAD	performance and an and a second secon	CTANDAL II CONTRACT II SUPPORT ADD II SUPPO	407ARRED 99 moderne to objective second a source of the objective second a source of the objective second a source of the objective of the objective second a source of the objective of the objective second a source of the objective of the objective of the objective second a source of the objective of the objective of the objective second a source of the objective of the objecti		ATTRACTOR IN ANY ANY ANY ANY ANY ANY ANY ANY ANY AN			
	monotanemisti and an and an	Mada n			VCTUADEDCO VCTUADECO VC	performance productions and and a second sec	Visional and a second s			ATRADUSD 34 Applements and applements applements ap	APPENDED III		
personal en fanosa en fanosa e	Incoderentials, and an ender and an ender an en	Healers			VCTRADBOOL VCTRAD	and observations and ob	VITANIANA IP     V	ACTIONED SI ACTIONED SI ACTIONED SI ANTI- Mandale III ANTI- Namedae III ANTI-	PC5003568 40	VERNOVE IS and the set of the set	Methodology at a second		
	monotenerstellen selectere A server and and an and an and an and an and and and an and an and an and an and and and and and an and an and an and					and desired and an and		VTSORED 9 and the second secon	ACTION III III IIII IIII IIIIIIIIIIIIIIIII	MPTRASSID 24 American			
unitaria unitar	<ul> <li>Antipation and a second and a s</li></ul>					And Barris And Annual A	Virtuidat la Sinta de la constanti de Sinta de la constanti de Sint	VISIONE 9		MITENSION IN APPROXIMATION OF A DESCRIPTION APPROXIMATION OF A DESCRIPTION OF A DESCRIPTION APPROXIMATION OF A DESCRIPTION OF A DESCRIPTION APPROXIMATION OF A DESCRIPTION OF A DESCRIPTION OF A DESCRIPTION APPROXIMATION OF A DESCRIPTION OF A DESCRIPTION OF A DESCRIPTION APPROXIMATION OF A DESCRIPTION OF A DESCRIPTION OF A DESCRIPTION APPROXIMATION OF A DESCRIPTION OF A DESCRIPTION APPROXIMATION OF A DESCRIPTION OF A DESCRIPTIONO	APPENDENCE II APPENDENCE II APPEND		
	<ul> <li>Antipational and antipational antiteational antipational antipational antipational antipational</li></ul>							VTRUELS 9 VTRUELS 9 VTRUELS 20 VTRUELS	Constraint and a second sec	ANNOUS I A	NINOSSI JI NINOSSI JI NINOSI JI NINOSI JI NINOSI JI NINOSI JI NINOSSI JI NINOSSI JI NINO		
	<ul> <li>Another and a second sec</li></ul>						VIRUNAL IS VIRUNAL IS VIRUNA	<ul> <li>Control of a second second seco</li></ul>					
	Anothermonie of the sector of						EVENING 19     E	NNRIA B	KONDOR (I	NUMBER J	NINGKON U NINGKON U NINGKO		
	An observations and an observations A second and an observations and an observations an observati						Vinited a second	AVIOLOGI II AVIOLOGI II AVIOLI					
		Pinkan n manga a sa angan a sa an						SYNEKA N		ANNOUS 1			
								SNRIG 9		I Construction of the second s			
								AVNERS 8					
							NNITION I CONTRACTORY CONTRACT	AVISIO 2					
		Network						Avies 1					
								NVMKKA N NVMKKA N NVMKA NVMKA N NVMKA NVMKA N			Stores a grant and a gr		
								NVISION IN CONTRACTOR OF CONTO					
								NVIGUO S					

**FIGURE 1** Comprehensive summary data on drug repurposingfocused COVID-19 clinical trials completed, in progress, or in advanced planning stages as of 17 April 2020. Trial data were organized according to drug and target or pharmacologic mechanism, along with results and pertinent literature from any preliminary COVID-19 studies (or prior SARS and MERS studies), trial ID and phase, and data on investigational scale and structure including number of participants, blinding, single- vs. multi-centre status and estimated completion date phase, scale, expected completion date and other key descriptors. The tested modalities attempt a variety of approaches to improve patient outcomes, some targeting the virus directly, others seeking to counter its deleterious physiological sequelae through immunomodulation or respiratory and circulatory support to reduce mortality and morbidity.

Summary statistics for these seminal trials are provided in Figure 2. As can be seen, drugs and targets linked to unique viral components and processes-such as the viral protease and RNAdependent RNA polymerase-have predominated in early investigations. Several compounds had demonstrated promise in at least some preliminary studies including lopinavir/ritonavir, remdesivir, and chloroquine or hydroxychloroquine, and more than a third (for which comprehensive descriptions were provided) were already at or beyond phase 3. Nevertheless, the scale of most trials remains small, the vast majority are not multi-centred, and evaluation of efficacy will take months or years to carry out. Only a few clinical trials are enrolling greater than 1,000 participants, including the global WHO DISCOVERY trial, the European-based INSERM trial and the Adaptive COVID-19 Treatment Trial. Moreover, the most commonly tested drugs have been drawn from anti-viral studies outside the prior body of research focusing on SARS and MERS.

Since the SARS and MERS outbreaks dissipated without approaching the global impact of COVID-19, fledgling therapeutic studies for these epidemics were generally not followed up. As a result, in vivo animal and human data for promising drug prospects, including blood concentrations and dose-response curves in animal studies, are largely unavailable. This has likely contributed to the pronounced preference, in existing COVID-19 clinical investigations, to repurpose therapeutic candidates like favipiravir, remdesivir and lopinavir/ritonavir, all designed for taxonomically distinct viruses and viral classes (particularly HIV, Ebola and influenza) relative to SARS-CoV-2. These therapeutic agents nonetheless benefit from prior in vivo data which the compounds effective against SARS-CoV and MERS-CoV lack, making them more readily adaptable to urgent COVID-19 clinical trials than drug candidates for fellow betacoronaviruses with higher likelihood of specific interactions with SARS-CoV-2 essential components.

Such factors, largely a product of practical urgencies amid a pressing pandemic and the contingent history of the SARS and MERS epidemics, further suggest that there may be substantial overlooked potential for new COVID-19 drugs showing prior promise in vitro against other betacoronaviruses. This suggestion is reinforced by a recent study which noted significant in vitro and in vivo activity of a known nucleoside analogue with previous efficacy against SARS and MERS,  $\beta$ -D-N4-hydroxycytidine (NHC), in reducing viral load in cell culture and tissue damage in mice secondary to SARS-CoV-2 infection (Sheahan et al., 2020). NHC was one of nearly a dozen drugs to have demonstrated potential in reducing the disease burden from SARS, MERS or both (De Clercq, 2006; Kumar, Jung, & Liang, 2013; Savarino, 2005), and the recent results support the notion that such repurposing may be fruitful for COVID-19.

We have therefore systematically combed available literature, reports and commentaries to ascertain untested drugs with previous



**FIGURE 2** Cumulative statistics from drug repurposing-focused COVID-19 clinical trials, based on the aggregate number of trials (out of a total of 53 publicly reported by 17 April 2020) involving (a) a specific drug, (b) a classifying target or mechanism, (c) clinical research phase, (d) single centre vs. multi-centre and (e) a given expected timeframe for reporting results

promise for SARS and MERS that merit consideration for additional COVID-19 trials, alongside the comprehensive clinical trial data elaborated previously. We utilized an approach combining careful manual curation and algorithmic scraping using a flexible Python language-based text-mining tool, previously developed for research into prospective repurposable drugs for Duchenne muscular dystrophy. Concomitantly, we systematically examined the drugs with previous reported efficacy in the context of SARS and MERS, and then curated them on the basis of several factors most indicative of potential in clinical trials to repurpose them for SARS-CoV-2.

In assessing criteria to identify highly promising candidates for COVID-19 drug repurposing, it has been noted that perhaps the primary predictor of eventual failure in clinical trials is non-selectivity for the target, contributing to unacceptable toxicity (Gayvert, Madhukar, & Elemento, 2016). Therefore, in examining the as yet untested or seldom-tested SARS and MERS drugs with potential for COVID-19 repositioning, particular weighting was given to those exhibiting a low reported  $EC_{50}$  (or  $IC_{50}$ ) and high Selectivity Index (SI) from cell culture studies. Attention was likewise given to drugs which are not only selective for a viral target, especially a component indispensable for viral replication, but also substantially reduce viral load in vitro. Further consideration was given for modalities demonstrating confirmation of potential efficacy from multiple centres. With these factors as primary criteria for identifying COVID-19 drug repurposing candidates, several especially promising potential therapeutics were identified, which is summarized in Figure 3.

315

Of particular promise are a docking octapeptide, AVLQSGFR (Chou, Wei, & Zhong, 2003; Gan et al., 2006), and a Phe-Phe dipeptide inhibitor, 18c (Shie et al., 2005), with marked selectivity (> 1,000-fold) for the betacoronaviral protease of SARS-CoV (3C-like protease, also known as 3Cl protease, 3CLpro or Mpro) and demonstrated capacity to reduce viral load in cell culture. Both agents exhibit not only remarkable Selectivity Index (SI) values, but also low IC<sub>50</sub> and/or EC<sub>50</sub> measurements that suggest viability as practical drugs in vivo. As noted previously, the viral protease is also the most frequent target of COVID-19 clinical trials currently in progress or planning, but these candidates stand out for their proven ability to selectively target 3CLpro and to bring about a tangible reduction in viral infection capacity.

Encouraging results have also been observed for bananin (Huang, Zheng, & Sun, 2008; Tanner et al., 2005; Wang et al., 2011), a viral helicase inhibitor with > 30-fold selectivity in cell culture studies; for calpain inhibitor VI (Barnard et al., 2004), with > 100-fold selectivity; -WILEY- Transboundary and Emerging Diseases

Drug	Target in SARS-CoV or MERS- CoV (if known)	Reported EC50 (EC90) or IC50 vs. viral replication or target activity in vitro	Selectivity Index (SI, if known)	Testing for viral load reduction in cells?	# positive reports	# independent groups reporting positive	DOIs and primary authors of principal references
AVLQSGFR (docking octapeptide)	3CL protease (Mpro)	EC50: 0.027 µg/ml	>3700	Y	2	2	doi.org/10.1016/S0006-291X(03)01342-1 (Chou et al., 2003), doi.org/10.1016/j.peptides.2005.09.006 (Gan et al., 2006)
18c (Phe-Phe dipeptide inhibitor)	3CL protease (Mpro)	EC50: 0.18 μM	>1000	Y	1	1	10.1016/j.bmc.2005.05.065 (Shie et al., 2003)
hesperetin	3CL protease (Mpro)	IC50: 8.3 µM	>300	Ν	1	1	10.1016/j.antiviral.2005.07.002 (Lin et al.)
cinanserin	3CL protease (Mpro)	IC50: 5 µМ, EC50: 19-34 µМ		Y	1	1	10.1128/JVI.79.11.7095-7103.2005 (Chen et al., 2005)
bananin	helicase	EC50: <10 µМ	>30	Y	3	3	10.1016/j.chembiol.2005.01.006 (Tanner et al., 2005), (PMID: 18708673, Huang et al., 2008), 10.1111/j.1742-4658.2010.07961.x (Wang et al., 2010)
calpain inhibitor VI (4- fluorophenyls ulfonyl Val-Leu[CHO ])	endosomal cathepsin-L-proteolysis	EC90: 3 µM	>100	Y	1	1	10.1177/095632020401500102 (Barnard et al., 2004)
nafamostat	TMPRSS2 (cellular serine protease), S protein priming	IC50: 0.1 µM		Y	1	1	10.1128/AAC.01043-16 (Yamamoto et al.)

**FIGURE 3** Summary data on promising untested candidates for COVID-19 drug repurposing based on proven success in SARS and/or MERS in vitro studies, with focus on target selectivity, viral load reduction and number of positive reports with independent confirmation

and for the herbal extract hesperetin (Lin et al., 2005), with an SI > 300 and a direct inhibitory effect on the 3Cl protease. Bananin (Tanner et al., 2005) and calpain inhibitor VI (Barnard et al., 2004) have likewise been found to inhibit viral load and infection in vitro. Promising seminal studies for inhibition of SARS or MERS infection have also emerged for another protease inhibitor, cinanserin (Chen et al., 2005), and for nafamostat (Yamamoto et al., 2016), a cellular serine protease inhibitor that reduces viral spike protein priming.

As indicated above, a limitation in evaluating these compounds' potential as COVID-19 treatments is that all reported studies thus far are in vitro, without data on therapeutic or toxic blood concentrations, ED50, or dose-response behaviour in animals—a result of the abrupt subsiding of the SARS and MERS epidemics. Yet, this very fact, in conjunction with their striking findings in cell culture studies, helps to underscore their untapped potential for the current pandemic caused by a much more persistent betacoronavirus, and the value of testing them in an in vivo context. Alongside the recent findings by Sheahan and coworkers with NHC, such results suggest that animal studies and preliminary clinical trials with these agents, or closely related chemical derivatives, may prove fruitful in expanding the arsenal of drugs to combat the relentless spread, morbidity and mortality of COVID-19.

#### ACKNOWLEDGEMENTS

The authors would like to acknowledge the valuable assistance of Florian Barthélémy, PhD, in helping to format the figures and illustrations for this manuscript.

#### CONFLICT OF INTEREST

The authors certify that they have no affiliations with, or involvement in, any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers' bureaus; membership, employment, consultancies, stock ownership, or other form of equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.

# ETHICAL APPROVAL

The authors confirm that the ethical policies of the journal, as noted on the journal's author guidelines page, have been adhered to. No ethical approval was required as this is a review article with no original research data.

#### DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this article as no new data were created or analysed in this study.

# ORCID

J. Wes Ulm D https://orcid.org/0000-0002-9224-4963

### REFERENCES

- Barnard, D. L., Hubbard, V. D., Burton, J., Smee, D. F., Morrey, J. D., Otto, M. J., & Sidwell, R. W. (2004). Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. *Antiviral Chemistry & Chemotherapy*, 15(1), 15–22. https://doi.org/10.1177/095632020401500102
- Chen, L., Gui, C., Luo, X., Yang, Q., Gunther, S., Scandella, E., ... Jiang, H. (2005). Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro. *Journal of Virology*, 79(11), 7095–7103. https:// doi.org/10.1128/jvi.79.11.7095-7103.2005
- Chou, K. C., Wei, D. Q., & Zhong, W. Z. (2003). Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. *Biochemical and Biophysical Research Communications*, 308(1), 148–151. https://doi.org/10.1016/s0006 -291x(03)01342-1
- De Clercq, E. (2006). Potential antivirals and antiviral strategies against SARS coronavirus infections. *Expert Review of Anti-infective Therapy*, 4(2), 291–302. https://doi.org/10.1586/14787210.4.2.291
- Gan, Y. R., Huang, H., Huang, Y. D., Rao, C. M., Zhao, Y., Liu, J. S., ... Wei, D. Q. (2006). Synthesis and activity of an octapeptide inhibitor designed for SARS coronavirus main proteinase. *Peptides*, 27(4), 622– 625. https://doi.org/10.1016/j.peptides.2005.09.006
- Gayvert, K. M., Madhukar, N. S., & Elemento, O. (2016). A data-driven approach to predicting successes and failures of clinical trials. *Cell Chemical Biology*, 23(10), 1294–1301. https://doi.org/10.1016/j. chembiol.2016.07.023
- Huang, J. D., Zheng, B. J., & Sun, H. Z. (2008). Helicases as antiviral drug targets. Hong Kong Medical Journal, 14(Suppl 4), 36–38.

- Kumar, V., Jung, Y. S., & Liang, P. H. (2013). Anti-SARS coronavirus agents: A patent review (2008 - present). Expert Opinion on Therapeutic Patents, 23(10), 1337–1348. https://doi.org/10.1517/13543 776.2013.823159
- Li, G., & De Clercq, E. (2020). Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery, 19(3), 149– 150. England. https://doi.org/10.1038/d41573-020-00016-0
- Lin, C. W., Tsai, F. J., Tsai, C. H., Lai, C. C., Wan, L., Ho, T. Y., ... Chao, P. D. (2005). Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. *Antiviral Research*, 68(1), 36–42. https://doi.org/10.1016/j.antiviral.2005.07.002
- Savarino, A. (2005). Expanding the frontiers of existing antiviral drugs: Possible effects of HIV-1 protease inhibitors against SARS and avian influenza. *Journal of Clinical Virology*, 34(3), 170–178. https://doi. org/10.1016/j.jcv.2005.03.005
- Sheahan, T. P., Sims, A. C., Zhou, S., Graham, R. L., Pruijssers, A. J., Agostini, M. L., ... Baric, R. S. (2020). An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. *Science Translational Medicine*, 12(541), eabb5883. https://doi.org/10.1126/scitransImed.abb5883
- Shie, J. J., Fang, J. M., Kuo, T. H., Kuo, C. J., Liang, P. H., Huang, H. J., ... Wong, C. H. (2005). Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha, beta-unsaturated esters. *Bioorganic & Medicinal Chemistry*, 13(17), 5240–5252. https:// doi.org/10.1016/j.bmc.2005.05.065
- Spinelli, A., & Pellino, G. (2020). COVID-19 pandemic: Perspectives on an unfolding crisis. British Journal of Surgery, 107(7), 785–787. https:// doi.org/10.1002/bjs.11627

- Tanner, J. A., Zheng, B. J., Zhou, J., Watt, R. M., Jiang, J. Q., Wong, K. L., ... Huang, J. D. (2005). The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. *Chemistry & Biology*, 12(3), 303–311. https://doi.org/10.1016/j. chembiol.2005.01.006
- Wang, Z., Huang, J. D., Wong, K. L., Wang, P. G., Zhang, H. J., Tanner, J. A., ... Niccolai, N. (2011). On the mechanisms of bananin activity against severe acute respiratory syndrome coronavirus. *FEBS Journal*, 278(2), 383–389. https://doi.org/10.1111/j.1742-4658.2010.07961.x
- Yamamoto, M., Matsuyama, S., Li, X., Takeda, M., Kawaguchi, Y., Inoue, J. I., & Matsuda, Z. (2016). Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus s protein-mediated membrane fusion using the split-protein-based cellcell fusion assay. Antimicrobial Agents and Chemotherapy, 60(11), 6532-6539. https://doi.org/10.1128/aac.01043-16
- Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., ... Tan, W. (2020). A novel coronavirus from patients with pneumonia in China, 2019. *New England Journal of Medicine*, 382(8), 727–733. https://doi. org/10.1056/NEJMoa2001017

How to cite this article: Ulm JW, Nelson SF. COVID-19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates. *Transbound Emerg Dis*. 2021;68:313–317. https://doi.org/10.1111/tbed.13710